GMAB Genmab PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: GMAB
- PE Ratio
As of May 16, 2025, the Genmab stock's PE ratio is 11.49. This takes into account the latest EPS of $1.73 and stock price of $19.88. The PE ratio marks a decrease of 33% from its last 4 quarters average of 17.0.
GMAB PE ratio history
The PE ratio of Genmab has averaged 41.97 over the last eight years. The current P/E ratio of 11.49 is 73% lower than the historical average. Looking back at the last eight years, GMAB's PE ratio peaked in the Jun 2021 quarter at 75.61, when the price was $40.83 and the EPS was $0.54. The lowest point was in the Mar 2025 quarter, when it reached 11.32 with a price of $19.58 and an EPS of $1.73.
Genmab PE ratio by year
Maximum annual increase: 57.53% in 2021
Maximum annual decrease: -64.37% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 12.2 | -64.37% | $20.87 | $1.71 |
| 2023 | 34.24 | -5.47% | $31.84 | $0.93 |
| 2022 | 36.22 | -42.32% | $42.38 | $1.17 |
| 2021 | 62.79 | 57.53% | $39.56 | $0.63 |
| 2020 | 39.86 | -14.32% | $40.66 | $1.02 |
| 2019 | 46.52 | -4.16% | $22.33 | $0.48 |
| 2018 | 48.54 | -26.79% | $16.5 | $0.34 |
| 2017 | 66.3 | N/A | $16.58 | $0.25 |
Genmab PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 11.32 | -7.21% | $19.58 | $1.73 |
| Dec 2024 | 12.2 | -48.46% | $20.87 | $1.71 |
| Sep 2024 | 23.67 | 13.04% | $24.38 | $1.03 |
| Jun 2024 | 20.94 | -17.4% | $25.13 | $1.2 |
| Mar 2024 | 25.35 | -25.96% | $29.91 | $1.18 |
| Dec 2023 | 34.24 | -13.6% | $31.84 | $0.93 |
| Sep 2023 | 39.63 | 4.26% | $35.27 | $0.89 |
| Jun 2023 | 38.01 | 11.73% | $38.01 | $1 |
| Mar 2023 | 34.02 | -6.07% | $37.76 | $1.11 |
| Dec 2022 | 36.22 | 35.25% | $42.38 | $1.17 |
| Sep 2022 | 26.78 | -30.77% | $32.13 | $1.2 |
| Jun 2022 | 38.68 | -46.55% | $32.49 | $0.84 |
| Mar 2022 | 72.36 | 15.24% | $36.18 | $0.5 |
| Dec 2021 | 62.79 | -10.91% | $39.56 | $0.63 |
| Sep 2021 | 70.48 | -6.78% | $43.7 | $0.62 |
GMAB Price vs fair value
GMAB average PE ratio chart
GMAB's current PE ratio is lower than its 3, 5 and 10-year averages.
GMAB PE vs peers
In comparison to its peer stocks AMGN and GILD, GMAB's PE ratio is lower. Genmab is currently trading at a lower PE ratio (11.49) than its peers average of 18.18.
| Stock name | PE ratio | Market cap |
|---|---|---|
| GMAB Genmab | 11.49 | $13.16B |
| BIIB Biogen Inc | 12.36 | $18.4B |
| REGN Regeneron Pharmaceuticals Inc | 14.23 | $64.17B |
| GILD Gilead Sciences Inc | 21.49 | $127.5B |
| AMGN Amgen Inc | 24.65 | $146.48B |
| INCY Incyte Corp | 218.31 | $12.25B |
| VRTX Vertex Pharmaceuticals Inc | N/A | $112.64B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $37.2B |
| MRNA Moderna Inc | N/A | $9.61B |
Frequently asked questions
What is Genmab's PE ratio?
GMAB stock has a price to earnings ratio of 11.49 as of May 16, 2025.
What is the 3-year average PE ratio for Genmab (GMAB)?
The average PE ratio for GMAB stock over the past 3 years is 28.42.
What is the 5-year average PE ratio for Genmab (GMAB)?
The average PE ratio for GMAB stock over the past 5 years is 37.34.
What is the highest PE ratio for GMAB?
Over the last eight years, the quarterly PE ratio reached its highest level at 75.61 in the Jun 2021 quarter.
How does the current PE ratio for GMAB compare to its historical average?
GMAB's price to earnings ratio is currently 73% below its 8-year historical average.
How is GMAB's PE ratio calculated (Genmab PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (May 16, 2025), Genmab's share price is $19.88. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.73. Therefore, Genmab's PE ratio for today is 11.49. PE RATIO(11.49) = STOCK PRICE($19.88) / TTM EPS($1.73)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.